Sector consensus Monte Rosa Therapeutics, Inc.

Stocks

Market Closed - Nasdaq 21:00:00 24/08/2026 BST			5-day change	1st Jan Change
13.78 ^USD	-3.67%		-11.13%	-12.15%

08-24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
08-24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Average Target P.	Objective/dr gap	Nbr of analysts
MONTE ROSA THERAPEUTICS, INC.	28.5	+99.3%	6
LONZA GROUP AG	681.13	+15.02%	23
REVOLUTION MEDICINES, INC.	223.24	+6.58%	21
IQVIA HOLDINGS INC.	275.17	+5.91%	18
BEONE MEDICINES AG	433.02	+15.63%	27
CELLTRION, INC.	266,031.64	+38.34%	23
MEDPACE HOLDINGS, INC.	581.83	-6.27%	12
ASCENDIS PHARMA A/S	268.37	+23.52%	19
EUROFINS SCIENTIFIC SE	72.53	-0.43%	14
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	281	-4.81%	14
ICON PUBLIC LIMITED COMPANY	185.56	+7.74%	16
TEMPUS AI, INC.	63.36	-12.84%	14
PHARMARON BEIJING CO., LTD.	47.08	-1.87%	11
BIO-TECHNE CORPORATION	70.73	-2.2%	11
ABIVAX	138.97	+36.51%	6
PRAXIS PRECISION MEDICINES, INC.	638.68	+69.89%	19
APOGEE THERAPEUTICS, INC.	134.85	+0.07%	11
PROTAGONIST THERAPEUTICS, INC.	170.38	+10.41%	13
KYMERA THERAPEUTICS, INC.	130.91	+9.27%	22
IONIS PHARMACEUTICALS, INC.	88	+47.3%	22
Average	13,527.25	+17.85%	16
Weighted average by Cap.	22,043.57	+13.44%	19